Off-the-shelf car t cells production using crispr/cas9 and mRNA technologies
Autologous chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy in hematologic malignancies but are limited by complex manufacturing, high costs, and variability due to patient-derived T cells. Allogeneic, off-the-shelf CAR T cells derived from healthy donors offer a promising solution...